Shinichi Arizono1,2, Taiki Furukawa3,4, Hiroyuki Taniguchi5, Koji Sakamoto3, Tomoki Kimura5, Kensuke Kataoka5, Tomoya Ogawa2, Fumiko Watanabe2, Yasuhiro Kondoh5. 1. School of Rehabilitation Sciences, Seirei Christopher University, Hamamatsu, Japan. 2. Department of Rehabilitation, Tosei General Hospital, Seto, Japan. 3. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. 4. Department of Medical IT Center, Nagoya University Graduate School of Medicine, Nagoya, Japan. 5. Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Abstract
BACKGROUND AND OBJECTIVE: The efficacy of supplemental oxygen during exercise remains unclear for patients with IPF, as there have been conflicting results from recent prospective studies with small sample sizes. METHODS: This prospective, single-blind, randomized, crossover trial evaluated the efficacy of supplemental oxygen compared with placebo air during exercise in consecutive patients with IPF without resting hypoxaemia at initial evaluation. Patients with <90% SpO2 in a 6MWT using room air were randomly assigned to a CWRET at 80% of peak work rate with oxygen or placebo air gas via nasal cannula at 4 L/min. The primary endpoint was the effect of supplemental oxygen on endurance time. RESULTS: We recruited 72 consecutive patients (median age: 66.5 years, % FVC: 84.6%, % DLCO : 61.4%). Supplemental oxygen significantly increased the endurance time (340-424 s; P < 0.001) and minimum SpO2 (88.0-94.0%; P < 0.001) compared with placebo air. Furthermore, supplemental oxygen significantly improved dyspnoea and leg fatigue. In a multivariate linear regression analysis, the endurance time on air was an independent explanatory variable of the improvement rate of endurance time (P = 0.02). CONCLUSION: In mild-moderate IPF with exercise-induced hypoxaemia even without resting hypoxaemia, supplemental oxygen during exercise improved the endurance time, desaturation and subjective symptoms. Patients with shorter endurance times with placebo air showed better improvement with supplemental oxygen.
RCT Entities:
BACKGROUND AND OBJECTIVE: The efficacy of supplemental oxygen during exercise remains unclear for patients with IPF, as there have been conflicting results from recent prospective studies with small sample sizes. METHODS: This prospective, single-blind, randomized, crossover trial evaluated the efficacy of supplemental oxygen compared with placebo air during exercise in consecutive patients with IPF without resting hypoxaemia at initial evaluation. Patients with <90% SpO2 in a 6MWT using room air were randomly assigned to a CWRET at 80% of peak work rate with oxygen or placebo air gas via nasal cannula at 4 L/min. The primary endpoint was the effect of supplemental oxygen on endurance time. RESULTS: We recruited 72 consecutive patients (median age: 66.5 years, % FVC: 84.6%, % DLCO : 61.4%). Supplemental oxygen significantly increased the endurance time (340-424 s; P < 0.001) and minimum SpO2 (88.0-94.0%; P < 0.001) compared with placebo air. Furthermore, supplemental oxygen significantly improved dyspnoea and leg fatigue. In a multivariate linear regression analysis, the endurance time on air was an independent explanatory variable of the improvement rate of endurance time (P = 0.02). CONCLUSION: In mild-moderate IPF with exercise-induced hypoxaemia even without resting hypoxaemia, supplemental oxygen during exercise improved the endurance time, desaturation and subjective symptoms. Patients with shorter endurance times with placebo air showed better improvement with supplemental oxygen.
Authors: Diana Badenes-Bonet; Pilar Cejudo; Anna Rodó-Pin; Clara Martín-Ontiyuelo; Roberto Chalela; Jose Antonio Rodríguez-Portal; Rosa Vázquez-Sánchez; Joaquim Gea; Xavier Duran; Oswaldo Antonio Caguana; Diego Agustín Rodriguez-Chiaradia; Eva Balcells Journal: BMC Pulm Med Date: 2021-11-08 Impact factor: 3.317
Authors: Filip Franciszek Karuga; Piotr Kaczmarski; Bartosz Szmyd; Piotr Białasiewicz; Marcin Sochal; Agata Gabryelska Journal: J Clin Med Date: 2022-08-26 Impact factor: 4.964